TY - JOUR
T1 - Tracking medication changes to assess outcomes in comparative effectiveness research
T2 - A bipolar CHOICE study
AU - Reilly-Harrington, Noreen A.
AU - Sylvia, Louisa G.
AU - Rabideau, Dustin J.
AU - Gold, Alexandra K.
AU - Deckersbach, Thilo
AU - Bowden, Charles L.
AU - Bobo, William V.
AU - Singh, Vivek
AU - Calabrese, Joseph R.
AU - Shelton, Richard C.
AU - Friedman, Edward S.
AU - Thase, Michael E.
AU - Kamali, Masoud
AU - Tohen, Mauricio
AU - McInnis, Melvin G.
AU - McElroy, Susan L.
AU - Ketter, Terence A.
AU - Kocsis, James H.
AU - Kinrys, Gustavo
AU - Nierenberg, Andrew A.
PY - 2016/11/15
Y1 - 2016/11/15
N2 - Background Comparative effectiveness research uses multiple tools, but lacks outcome measures to assess large electronic medical records and claims data. Aggregate changes in medications in response to clinical need may serve as a surrogate outcome measure. We developed the Medication Recommendation Tracking Form (MRTF) to record the frequency, types, and reasons for medication adjustments in order to calculate Necessary Clinical Adjustments (NCAs), medication adjustments to reduce symptoms, maximize treatment response, or address problematic side effects. Methods The MRTF was completed at every visit for 482 adult patients in Bipolar CHOICE, a 6-month randomized comparative effectiveness trial. Results Responders had significantly fewer NCAs compared to non-responders. NCAs predicted subsequent response status such that every additional NCA during the previous visit decreased a patient's odds of response by approximately 30%. Patients with more severe symptoms had a greater number of NCAs at the subsequent visit. Patients with a comorbid anxiety disorder demonstrated a significantly higher rate of NCAs per month than those without a comorbid anxiety disorder. Patients with greater frequency, intensity, and interference of side effects had higher rates of NCAs. Participants with fewer NCAs reported a higher quality of life and decreased functional impairment. Limitations The MRTF has not been examined in community clinic settings and did not predict response more efficiently than the Clinical Global Impression-Bipolar Version (CGI-BP). Conclusions The MRTF is a feasible proxy of clinical outcome, with implications for clinical training and decision-making. Analyses of big data could use changes in medications as a surrogate outcome measure.
AB - Background Comparative effectiveness research uses multiple tools, but lacks outcome measures to assess large electronic medical records and claims data. Aggregate changes in medications in response to clinical need may serve as a surrogate outcome measure. We developed the Medication Recommendation Tracking Form (MRTF) to record the frequency, types, and reasons for medication adjustments in order to calculate Necessary Clinical Adjustments (NCAs), medication adjustments to reduce symptoms, maximize treatment response, or address problematic side effects. Methods The MRTF was completed at every visit for 482 adult patients in Bipolar CHOICE, a 6-month randomized comparative effectiveness trial. Results Responders had significantly fewer NCAs compared to non-responders. NCAs predicted subsequent response status such that every additional NCA during the previous visit decreased a patient's odds of response by approximately 30%. Patients with more severe symptoms had a greater number of NCAs at the subsequent visit. Patients with a comorbid anxiety disorder demonstrated a significantly higher rate of NCAs per month than those without a comorbid anxiety disorder. Patients with greater frequency, intensity, and interference of side effects had higher rates of NCAs. Participants with fewer NCAs reported a higher quality of life and decreased functional impairment. Limitations The MRTF has not been examined in community clinic settings and did not predict response more efficiently than the Clinical Global Impression-Bipolar Version (CGI-BP). Conclusions The MRTF is a feasible proxy of clinical outcome, with implications for clinical training and decision-making. Analyses of big data could use changes in medications as a surrogate outcome measure.
KW - Big data
KW - Bipolar disorder
KW - Comparative effectiveness
KW - Electronic medical record
KW - Medication
UR - http://www.scopus.com/inward/record.url?scp=84978696348&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978696348&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2016.07.007
DO - 10.1016/j.jad.2016.07.007
M3 - Article
C2 - 27449548
AN - SCOPUS:84978696348
SN - 0165-0327
VL - 205
SP - 159
EP - 164
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -